The Role of Complex Translocations Associated with TP53 Somatic Mutations for Aiding Prognosis of Canine Diffuse Large B cell Lymphoma When Treated with Standard of Care CHOP Chemotherapy

Lymphoma accounts for up to 24% of all cancers diagnosed in pet dogs. Among these cases diffuse large B-cell lymphoma (DLBCL) is the most common subtype. Despite continued advances in veterinary medicine, the response to treatment for canine lymphoma remains highly variable with no reliable means to predict response. 

Read more

Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma

Canine lymphoma is one of the most common cancers in dogs. While some breeds appear more at risk than others, all can be affected. While often treatable, canine lymphoma can rarely be cured. A continued understanding of the mechanisms causing lymphoma in dogs and identification of novel therapies are needed to improve survival in dogs with lymphoma. 

Read more

Harnessing a Dog’s Own Immune System to Kill Lymphoma Tumor Cells

Lymphoma is the most common malignancy of dogs representing up to 25% of diagnosed cancers. Dogs often develop an aggressive form of lymphoma that is rarely curable, with most unfortunately succumbing to disease within 12 months of diagnosis despite best-available chemotherapies. Dr. Wilson will develop a new treatment to re-train the dog’s own immune system to attack the most common type of canine lymphoma, B-cell lymphoma.

Read more